RxDoctor Payments Data

Amy Berretta

Psychiatric/Mental Health · New City, NYNPI 1497110696

Payments from drug & device makers

$7,135in general payments, 2019–2025

Across 361 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$982
  • Axsome Therapeutics, Inc.$542
  • Corium, LLC$305
  • Supernus Pharmaceuticals, Inc.$299
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$7,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,135 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$77,417
Medicare patients
75
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$58,196
VraylarCariprazine Hcl31$43,225
CaplytaLumateperone Tosylate11$19,484
VyvanseLisdexamfetamine Dimesylate20$8,120
Duloxetine Hcl82$3,112
Bupropion XlBupropion Hcl94$1,840
Vilazodone Hcl24$1,540
Escitalopram Oxalate121$805
Hydroxyzine Hcl52$730
Quetiapine Fumarate78$661
Mirtazapine70$643
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$557
Trazodone Hcl64$515
Clonazepam80$502
Buspirone Hcl54$498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,260$58,19633 claims
AbbVieVraylar$2,298$43,22531 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$982$19,48411 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$87$8,12020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in New City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →